News VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-06 pm EDT			5-day change	1st Jan Change
2.71 ^USD	+3.44%		+3.04%	+16.31%

May. 06	VYNE Therapeutics Says US FDA Clears its Investigational New Drug Application for Potential Autoimmune Treatment	MT
Apr. 04	Transcript : VYNE Therapeutics Inc. - Special Call

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

VYNE Therapeutics Says US FDA Clears its Investigational New Drug Application for Potential Autoimmune Treatment	May. 06	MT
VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor	May. 06	AQ
Vyne Therapeutics Announces FDA Clearance of IND Application for Vyn202, A Novel Bd2-Selective Bet Inhibitor	May. 06	CI
VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting	May. 01	AQ
Transcript : VYNE Therapeutics Inc. - Special Call	Apr. 04
VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference	Mar. 19	AQ
VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
VYNE Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q4 Revenue $76,000	Feb. 29	MT
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update	Feb. 29	AQ
VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium	Feb. 27	AQ
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference	Feb. 21	AQ
VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo	Jan. 10	AQ
VYNE Therapeutics Inc. Announces Positive Biomarker Data from Successful Phase 1B Trial of VYN201 for the Treatment of Vitiligo	Jan. 10	CI
VYNE Therapeutics Inc. Appoints Christine Borowski, Ph.D., to Its Board of Directors	Jan. 03	CI
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors	Jan. 03	AQ
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 Revenue $114,000	Nov. 13	MT
VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update	Nov. 13	AQ
Transcript : VYNE Therapeutics Inc. - Special Call	Nov. 09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Summary

Filters